
Benzinga Pro data, MaxCyte (NASDAQ:MXCT) reported Q4 sales of $10.15 million. Earnings fell to a loss of $4.87 million, resulting in a 81.85% decrease from last quarter. MaxCyte collected $10.14 million in revenue during Q3, but reported earnings showed a $2.68 million loss.